A Phase I, Open-label, Single-Centre, Drug-Drug Interaction Study to Evaluate the Influence of MT-3995 on Pharmacokinetics(PK) and Pharmacodynamics of Warfarin in Healthy Subjects
Latest Information Update: 10 Apr 2023
At a glance
- Drugs Apararenone (Primary) ; Warfarin
- Indications Diabetic neuropathies; Hypertension; Non-alcoholic steatohepatitis
- Focus Pharmacokinetics
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 02 Nov 2020 Results pooled analysis of data from 3 phase I studies drug drug interaction findings with apararenone (MT-3995), published in the Clinical Therapeutics
- 08 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Aug 2015 New trial record